Caribou Biosciences (CRBU) Receivables (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Receivables data on file, last reported at $1.7 million in Q1 2026.

• Quarterly Receivables fell 13.46% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (down 13.46% YoY) and the FY2025 annual result came in at $1.1 million, down 48.64% from the prior year.
• Receivables improved to $1.7 million in Q1 2026 per CRBU's latest filing, from $1.1 million in the prior quarter.
• Across five years, Receivables topped out at $3.6 million in Q2 2022 and bottomed at $1.1 million in Q4 2025.
• The 5-year median for Receivables is $2.1 million (2024), against an average of $2.3 million.
• The widest annual swing landed in 2022, when Receivables sank 63.1%; it then jumped 71.47% in 2023.
• Tracing CRBU's Receivables over 5 years: stood at $2.4 million in 2022, then fell by 0.61% to $2.4 million in 2023, then declined by 14.01% to $2.1 million in 2024, then slumped by 48.64% to $1.1 million in 2025, then surged by 55.53% to $1.7 million in 2026.
• Per Business Quant, the three latest CRBU Receivables figures stand at $1.7 million (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025).

Peer Comparison